AI Article Synopsis
- Transgenic models are crucial for understanding and developing treatments for Alzheimer's Disease (AD), each model displaying distinct behaviors and pathologies based on familial AD gene mutations.
- This review highlights advancements in transgenic mouse models, including China's initial model focusing on a specific gene mutation (PSEN1 V97L) found in familial AD cases.
- It also discusses how these models have contributed to preclinical drug findings and their potential role in investigating the underlying mechanisms of AD and developing multitarget therapies.
Article Abstract
Transgenic models are useful tools for studying the pathogenesis of and drug development for Alzheimer's Disease (AD). AD models are constructed usually using overexpression or knock-in of multiple pathogenic gene mutations from familial AD. Each transgenic model has its unique behavioral and pathological features. This review summarizes the research progress of transgenic mouse models, and their progress in the unique mechanism of amyloid-β oligomers, including the first transgenic mouse model built in China based on a single gene mutation (PSEN1 V97L) found in Chinese familial AD. We further summarized the preclinical findings of drugs using the models, and their future application in exploring the upstream mechanisms and multitarget drug development in AD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s11427-022-2357-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!